Asia Sikora Kessler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Asia Sikora Kessler has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Montserrat Vera-Llonch
Ionis Pharmaceuticals Inc, (Sikora Kessler, Tsimikas, and Vera-Llonch), Carlsbad, CA, USA
5 shared publications- Seth Joshua Baum
Flourish Research, Boca Raton, FL, USA (Dr Baum)
5 shared publications Daniel E. Soffer
University of Pennsylvania, (Soffer), Philadelphia, PA, USA
4 shared publicationsEmily Kutrieb
Avalere Health, Boston, MA, USA
3 shared publicationsMontserrat Vera Llonch
Ionis Pharmaceuticals Inc, Boston, MA, USA
3 shared publicationsSeth J. Baum
Flourish Research, Boca Raton, FL, USA
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260069
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia causing recurrent acute pancreatitis (AP). Since FCS is a genetic deficiency in functional lipoprotein lipase, conventional triglyceride-lowering therapies are ineffective in this metabolic disorder. Apolipoprotein C-III (apoC-III) inhibitors, including volanesorsen and olezarsen, have emerged as targeted treatments for FCS. Aim: To compare the efficacy and safety of olezarsen 80 mg every four weeks (Q4W) versus volanesorsen 300 mg weekly (QW) in patients with FCS using an anchored matching-adjusted indirect comparison. Materials & methods: Individual patient data from the Balance trial of olezarsen (n = 45) were weighted to match baseline characteristics reported in the APPROACH trial of volanesorsen (n = 66). Outcomes included percent change in fasting triglycerides (TG) and apoC-III at 26 and 52 weeks, and risks of AP events and adverse events at 52 weeks. Results: At 52 weeks, mean differences in fasting TG and apoC-III were -27.4% (95% CI: -69.4, 14.5) and -21.3% (95% CI: -61.9, 19.3). Relative risks of AP, treatment-emergent adverse events, and serious adverse events were 0.23 (95% CI: 0.01, 5.02), 0.87 (95% CI: 0.66, 1.13) and 0.50 (95% CI: 0.08, 3.26) at week 52. The rate ratio for AP events per patient-year was 0.06 (95% CI: 0.003, 1.41). No comparisons were statistically significant. Conclusion: In this matching-adjusted indirect comparison, no statistically significant differences in outcomes were observed between olezarsen and volanesorsen in patients with FCS. These findings provide important comparative context in a setting where head-to-head evidence is unavailable.
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260069
Open AccessComparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia causing recurrent acute pancreatitis (AP). Since FCS is a genetic deficiency in functional lipoprotein lipase, conventional triglyceride-lowering therapies are ineffective in this metabolic disorder. Apolipoprotein C-III (apoC-III) inhibitors, including volanesorsen and olezarsen, have emerged as targeted treatments for FCS. Aim: To compare the efficacy and safety of olezarsen 80 mg every four weeks (Q4W) versus volanesorsen 300 mg weekly (QW) in patients with FCS using an anchored matching-adjusted indirect comparison. Materials & methods: Individual patient data from the Balance trial of olezarsen (n = 45) were weighted to match baseline characteristics reported in the APPROACH trial of volanesorsen (n = 66). Outcomes included percent change in fasting triglycerides (TG) and apoC-III at 26 and 52 weeks, and risks of AP events and adverse events at 52 weeks. Results: At 52 weeks, mean differences in fasting TG and apoC-III were -27.4% (95% CI: -69.4, 14.5) and -21.3% (95% CI: -61.9, 19.3). Relative risks of AP, treatment-emergent adverse events, and serious adverse events were 0.23 (95% CI: 0.01, 5.02), 0.87 (95% CI: 0.66, 1.13) and 0.50 (95% CI: 0.08, 3.26) at week 52. The rate ratio for AP events per patient-year was 0.06 (95% CI: 0.003, 1.41). No comparisons were statistically significant. Conclusion: In this matching-adjusted indirect comparison, no statistically significant differences in outcomes were observed between olezarsen and volanesorsen in patients with FCS. These findings provide important comparative context in a setting where head-to-head evidence is unavailable.
- Open Access
- 7 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (7) , 1503-1507
Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison
- 7 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (7) , 1503-1507
Open AccessComparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison
- Open Access
- 27 April 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 644-646
Healthcare resource use for acute pancreatitis in patients with familial chylomicronemia syndrome treated with olezarsen
- 27 April 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 644-646
Open AccessHealthcare resource use for acute pancreatitis in patients with familial chylomicronemia syndrome treated with olezarsen
- Open Access
- 11 April 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (6) , 1097-1108
A real-world study on the risk of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia
- 11 April 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (6) , 1097-1108
Open AccessA real-world study on the risk of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia
- Open Access
- 3 March 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Correction: Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice
- 3 March 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Open AccessCorrection: Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice
- Open Access
- 19 December 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 299-309
Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome
- 19 December 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 299-309
Open AccessOlezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome
- Open Access
- 20 November 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 24
Temporal patterns of triglyceride testing and test results among adults with severe or extreme hypertriglyceridemia in US clinical practice
- 20 November 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 24
Open AccessTemporal patterns of triglyceride testing and test results among adults with severe or extreme hypertriglyceridemia in US clinical practice
- Open Access
- 28 July 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 252
Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice
Background: Severe and extreme hypertriglyceridemia (sHTG [TG 500–879 mg/dL; 5.65–9.93 mmol/L]; eHTG [TG ≥ 880 mg/dL; ≥ 9.94 mmol/L]) are important risk factors for acute pancreatitis (AP) and cardiovascular (CV) events. The objective of this study was to estimate rates of AP and CV events for adults with (and without) sHTG/eHTG in US clinical practice. Methods: A retrospective design and data from the MarketScan Research Databases were employed. Study population comprised adults with ≥ 1 TG value and was stratified by index TG (< 150, 150–499, 500–879, ≥ 880 mg/dL; < 1.69, 1.69–5.64, 5.65–9.93, ≥ 9.94 mmol/L). AP/CV events (per 1,000 person-years [PY]) were ascertained from index TG through end of study period, and were estimated for TG-specific subgroups and selected subsets defined therein. Results: Study population totaled 1.8 M adults (TG < 150 mg/dL [< 1.69 mmol/L]: N = 1.3 M; TG 150–499 mg/dL [1.69–5.64 mmol/L]: N = 449 K; TG 500–879 mg/dL [5.65–9.93 mmol/L]: N = 12,050; TG ≥ 880 mg/dL [≥ 9.94 mmol/L]: N = 3,944). AP rates (per 1,000 PY) increased from lowest to highest TG value (0.6 [< 150 mg/dL; < 1.69 mmol/L]) to 9.9 [≥ 880 mg/dL; ≥ 9.94 mmol/L]); rates were highest for adults with TG ≥ 880 mg/dL (≥ 9.94 mmol/L) and history of AP (193.0), pre-existing diabetes (13.9), or history of LLT (13.9). CV event rates (per 1,000 PY) also increased from lowest to highest TG value (3.3 [< 150 mg/dL; < 1.69 mmol/L]) to 10.3 [≥ 880 mg/dL; ≥ 9.94 mmol/L]); rates were highest for adults with TG ≥ 880 mg/dL (≥ 9.94 mmol/L) and history of CV events (116.5), pre-existing diabetes (18.1), or history of LLT (14.5). Conclusion: Rates of AP/CV events are substantially higher among adults with elevated TG values, and are especially high among adults with sHTG or eHTG, in particular those with these conditions and other risk factors. Understanding the magnitude of disease risk among sHTG/eHTG patients, with increasing TG levels as well as within important subgroups, is critical to improving patient care and outcomes.
- 28 July 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 252
Open AccessRates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice
Background: Severe and extreme hypertriglyceridemia (sHTG [TG 500–879 mg/dL; 5.65–9.93 mmol/L]; eHTG [TG ≥ 880 mg/dL; ≥ 9.94 mmol/L]) are important risk factors for acute pancreatitis (AP) and cardiovascular (CV) events. The objective of this study was to estimate rates of AP and CV events for adults with (and without) sHTG/eHTG in US clinical practice. Methods: A retrospective design and data from the MarketScan Research Databases were employed. Study population comprised adults with ≥ 1 TG value and was stratified by index TG (< 150, 150–499, 500–879, ≥ 880 mg/dL; < 1.69, 1.69–5.64, 5.65–9.93, ≥ 9.94 mmol/L). AP/CV events (per 1,000 person-years [PY]) were ascertained from index TG through end of study period, and were estimated for TG-specific subgroups and selected subsets defined therein. Results: Study population totaled 1.8 M adults (TG < 150 mg/dL [< 1.69 mmol/L]: N = 1.3 M; TG 150–499 mg/dL [1.69–5.64 mmol/L]: N = 449 K; TG 500–879 mg/dL [5.65–9.93 mmol/L]: N = 12,050; TG ≥ 880 mg/dL [≥ 9.94 mmol/L]: N = 3,944). AP rates (per 1,000 PY) increased from lowest to highest TG value (0.6 [< 150 mg/dL; < 1.69 mmol/L]) to 9.9 [≥ 880 mg/dL; ≥ 9.94 mmol/L]); rates were highest for adults with TG ≥ 880 mg/dL (≥ 9.94 mmol/L) and history of AP (193.0), pre-existing diabetes (13.9), or history of LLT (13.9). CV event rates (per 1,000 PY) also increased from lowest to highest TG value (3.3 [< 150 mg/dL; < 1.69 mmol/L]) to 10.3 [≥ 880 mg/dL; ≥ 9.94 mmol/L]); rates were highest for adults with TG ≥ 880 mg/dL (≥ 9.94 mmol/L) and history of CV events (116.5), pre-existing diabetes (18.1), or history of LLT (14.5). Conclusion: Rates of AP/CV events are substantially higher among adults with elevated TG values, and are especially high among adults with sHTG or eHTG, in particular those with these conditions and other risk factors. Understanding the magnitude of disease risk among sHTG/eHTG patients, with increasing TG levels as well as within important subgroups, is critical to improving patient care and outcomes.
- Open Access
- 18 June 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (5) , 1243-1255
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
- 18 June 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (5) , 1243-1255
Open AccessPatient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
- Open Access
- 10 April 2025
- Published by Elsevier in Journal of Clinical Lipidology
A qualitative study to explore the patient experience of hypertriglyceridemia-related acute pancreatitis
- 10 April 2025
- Published by Elsevier in Journal of Clinical Lipidology
Open AccessA qualitative study to explore the patient experience of hypertriglyceridemia-related acute pancreatitis